Evidence map›Paper›PMID 31005229›Full record

ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2019

Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy.

Christopher L Tinkle, Noelle L Williams, Huiyun Wu, Jianrong Wu, Sue C Kaste, Barry L Shulkin, Aimee C Talleur, Jamie E Flerlage, Melissa M Hudson, Monika L Metzger and 1 more

Open access · greenAbstract read
In one paragraph

Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Christopher L TinkleDepartment of Radiation Oncology, St. Jude Children's Hospital, Memphis, United States. Electronic address: christopher.tinkle@stjude.org.
Noelle L WilliamsDepartment of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, United States.
Huiyun WuDepartment of Biostatistics, St. Jude Children's Research Hospital, Memphis, United States.
Jianrong WuDepartment of Biostatistics, University of Kentucky, Lexington, United States.
Sue C KasteDepartment of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, United States; Department of Radiology, University of Tennessee Health Science Center, Memphis, United States; Department of Oncology, St. Jude Children's Research Hospital, Memphis, United States.
Barry L ShulkinDepartment of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, United States; Department of Radiology, University of Tennessee Health Science Center, Memphis, United States.
Aimee C TalleurDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, United States.
Jamie E FlerlageDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, United States.
Melissa M HudsonDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, United States.
Monika L MetzgerDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, United States.
Matthew J KrasinDepartment of Radiation Oncology, St. Jude Children's Hospital, Memphis, United States.
St. Jude Children's Research Hospital · USThomas Jefferson University · USUniversity of Kentucky · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
NCI NIH HHS P30 CA021765
6 · The paper itself

Abstract

background and purposeThe use of radiotherapy (RT) for pediatric patients with Hodgkin lymphoma (HL) experiencing disease progression or recurrence (15%) is controversial. We report treatment patterns and outcomes for pediatric patients with refractory/recurrent HL (rrHL) treated with curative-intent RT. MATERIALS AND

methodsForty-six patients with rrHL treated with salvage RT at our institution were identified. All received risk-adapted, response-based frontline therapy and were retrieved with cytoreductive regimens followed by RT to failure sites, with or without autologous hematopoietic cell transplantation (AHCT). Cumulative incidence (CIN) of local failure (LF) and survival were estimated after salvage RT and regression models determined predictors of LF after salvage RT.

resultsRT was administered as part of frontline therapy in 70% of patients, omitted for early response assessment in 13%, or deferred for primary progression in 17%. AHCT was omitted in 20% of patients. Median initial and salvage dose/site were 25.5 Gy and 30.6 Gy, respectively. Eight patients experienced progression. Two died without progression (median follow-up from salvage RT = 3.8 years). The 5-year CIN of LF after salvage RT was 17.7% (95% confidence interval [CI], 8.2-30.2%). The 5-year freedom from subsequent treatment failure and overall survival (OS) was 80.1% (95% CI, 69.2-92.6%) and 88.5% (95% CI, 79.5-98.6%), respectively. Inadequate response to salvage systemic therapy (p = 0.048) and male sex (p = 0.049) were significantly associated with LF after salvage RT.

conclusionrrHL is responsive to salvage RT, with low LF rates after moderate doses. OS is excellent, despite refractory disease. Initial salvage therapy response predicts subsequent LF.

Indexed as

AdolescentAdultChildDisease ProgressionFemaleHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansMaleRecurrenceSalvage TherapyTransplantation, AutologousTreatment FailureYoung AdultHodgkin lymphomaLocal failurePediatricRadiation therapyRecurrentRelapsed

Identifiers

PMID31005229
PMCPMC6478442
OpenAlexW2912288666

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.